Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2018-11-29Clinical Trial Update: An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) [Phase 4]
Phase 4 open-label expanded access study of everolimus in advanced neuroendocrine tumors completed; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-08-14Clinical Trial Update: Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue [Phase 1, Phase 2]
A clinical trial update on combining everolimus with a radiolabeled somatostatin analogue for neuroendocrine tumors across Phase 1 and Phase…
-
CLINICAL_TRIALS trial_result · 2018-07-30Clinical Trial Update: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors [Phase 1]
A Phase 1 trial assessing safety and pharmacology of SNX-5422 plus Everolimus in neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2018-04-18Clinical Trial Update: A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer [Phase 2]
Phase 2 clinical trial update for cixutumumab (IMC-A12) in islet cell cancer, with completed status and posted results.
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study [Phase 2]
Clinical trial update outlines a rollover protocol for subjects who responded in Mateon Therapeutics' Phase 2 neuroendocrine tumor study 421…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-04-12FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
The FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc.
-
CLINICAL_TRIALS approval · 2018-04-09Clinical Trial Update: EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Marketing approval has been granted for Lutathera (lutetium-177 dotatate) for somatostatin receptor‑positive neuroendocrine tumors, includin…
-
CLINICAL_TRIALS trial_result · 2017-12-15Clinical Trial Update: Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) [Phase 2]
Phase II study of a subcutaneous depot formulation of octreotide in acromegaly and neuroendocrine tumors has completed with posted results.
-
CLINICAL_TRIALS research · 2017-12-13Clinical Trial Update: Psychosocial Screening for Neuroendocrine Tumor Patients
A clinical trial update describing psychosocial screening for patients with neuroendocrine tumors. The current study status is unknown.
-
CLINICAL_TRIALS trial_result · 2017-10-12Clinical Trial Update: 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors [Phase 1]
This update reports progress on a Phase 1 trial of the radiopharmaceutical 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine tumor…
-
CLINICAL_TRIALS trial_result · 2017-09-12Clinical Trial Update: Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor [Phase 2]
Phase 2 trial comparing capecitabine with dacarbazine vs capecitabine with temozolomide in advanced/metastatic gastrointestinal, pancreatic,…
-
CLINICAL_TRIALS withdrawal · 2017-08-25Clinical Trial Update: Dosimetry Guided PRRT With 90Y-DOTATOC [Phase 2]
A Phase 2 trial evaluating dosimetry-guided peptide receptor radionuclide therapy using 90Y-DOTATOC has been withdrawn. The study covered ne…
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: Study of Panobinostat in Patients With Neuroendocrine Tumors [Phase 2]
Phase 2 trial of panobinostat in patients with neuroendocrine tumors was terminated; results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-03Clinical Trial Update: Lithium for Low-Grade Neuroendocrine Tumors [Phase 2]
Phase 2 clinical trial evaluating lithium for low-grade neuroendocrine tumors has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-04-17Clinical Trial Update: Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors [Phase 2]
A Phase 2a trial of desipramine in small cell lung cancer and other high-grade neuroendocrine tumors was terminated, with results posted in …
-
CLINICAL_TRIALS trial_result · 2017-03-03Clinical Trial Update: A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors [Phase 2]
Phase II study of pertuzumab in combination with erlotinib for metastatic or unresectable neuroendocrine tumors was terminated, with results…
-
CLINICAL_TRIALS trial_result · 2017-01-30Clinical Trial Update: Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies
A clinical trial evaluating perfusion CT to predict treatment response in hepatic malignancies has been terminated; the update does not repo…
-
FDA approval · 2017-01-20FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE) submitted by Advanced Accelerator Applications USA, Inc.
-
FDA approval · 2016-09-02FDA Approved: NETSPOT — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for NETSPOT (68Ga-DOTATATE), a radiopharmaceutical imaging agent for somatostatin receptor–positive …
-
CLINICAL_TRIALS trial_result · 2016-07-21Clinical Trial Update: Combination Targeted Radiotherapy in Neuroendocrine Tumors [NA]
This document reports a completed clinical trial evaluating combination targeted radiotherapy in neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2016-06-22Clinical Trial Update: Capecitabine and Temozolomide for Neuroendocrine Cancers [Phase 2]
Phase 2 trial evaluating the combination of capecitabine and temozolomide in neuroendocrine tumors has completed with results posted in 2016…
-
CLINICAL_TRIALS trial_result · 2016-05-06Clinical Trial Update: Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors [Phase 3]
A Phase 3 trial evaluating systemic therapy with or without upfront transarterial embolization for inoperable liver metastases from neuroend…
-
CLINICAL_TRIALS trial_result · 2016-03-30Clinical Trial Update: RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation [Phase 4]
A Phase 4 trial evaluating everolimus (RAD001) in combination with paclitaxel and carboplatin as first-line therapy for advanced large cell …
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) [NA]
This clinical trial update reports on imaging neuroendocrine tumors using PET with the radiotracer Fluoro-18-DOPA (F-DOPA); the study status…
-
CLINICAL_TRIALS trial_result · 2015-08-07Clinical Trial Update: DOTA-TOC in Metastasized Neuroendocrine Tumors [Phase 2]
This document reports the completion of a Phase 2 trial evaluating DOTA-TOC in metastasized neuroendocrine tumors.